ArticleTranslational oncology2026
Sohlh2 inhibited the angiogenesis of hepatocellular carcinoma through the HIF-1α/VEGFA pathway.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the role of Sohlh2 in hepatocellular carcinoma (HCC) and its potential mechanisms.
methodsThis study focused on Hep3B and HepG2 cells and employed lentiviral transfection to create Sohlh2 overexpression and knockdown models. Through CCK8, flow cytometry, angiogenesis and immunofluorescence experiments, the effects of Sohlh2 on tumor cell proliferation, cell cycle progression, apoptosis, and angiogenesis were investigated. Additionally, its regulatory role in the HIF-1α/VEGFA pathway was explored. The experiments were repeated after introducing the Sohlh2 agonist CoCl
resultExperimental results indicated that Sohlh2 was highly expressed in normal human hepatocytes but was downregulated in HCC cells. Overexpression of Sohlh2 inhibited HCC cell proliferation by blocking the transition from the G0/G1 phase to the S phase, promoted apoptosis, suppressed the expression of HIF-1α and CD31, and consequently inhibited tumor angiogenesis. Conversely, downregulation produced the opposite effects. In vivo and in vitro mechanistic studies indicated that HIF-1α agonists reversed the anti-proliferative, pro-apoptotic, and anti-angiogenic effects induced by Sohlh2 overexpression in HCC. Conversely, the antagonist LW6 significantly mitigated the effects of Sohlh2 knockdown.
conclusionOur research suggested that that Sohlh2 exerted a tumor-suppressing gene function in hepatocellular carcinoma by inhibiting the HIF-1α/VEGFA signaling pathway. These findings provided a potential molecular target for the development of anti-angiogenic therapies in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.